Pharmaxis Announces Major Company Restructure – Sale of Mannitol Business and Creation of Syntara; a Clinical-Stage Drug Development Company

3rd Oct 23

Release Date: 03/10/2023 9:05am

Pharmaxis Ltd (ASX: PXS) has announced details of the sale of the mannitol respiratory business which manufactures and supplies Aridol and Bronchitol to global markets and the formation of Syntara, a clinical stage drug development company primarily focusing on treatments for haematological malignancies (blood related cancers).

Key restructure features:

  • Sale of mannitol respiratory business to pharmaceutical manufacturing specialist, Arna Pharma 
  • Pharmaxis to be renamed Syntara1
  • Residual net exit costs of less than A$1m with Syntara to receive product royalties from Arna Pharma
  • Significant reduction in cost base: core expenses to be reduced by over 60% saving the company over A$14m per year
  • Syntara1 to primarily focus on clinical development.
  • Five planned clinical studies to deliver results in high unmet need diseases by mid-2025.

Lead drug candidate PXS-5505 to commence FDA agreed phase 2 trial in myelofibrosis in current quarter, Q4 2023

Read full media release - pdf

Categories: News and Media